CREATIC at PDA ATMP Conference 2025: Translating Innovation into Practice
Regina Demlová and Zora Čechová represented CREATIC at the PDA Parenteral Drug Association Advanced Therapy Medicinal Products Conference 2025, held under the theme “The Renaissance of Medicine: ATMPs and Maturing Perspectives.”
The conference offered a dense and highly practical programme focused on how advanced therapies move from scientific promise to real world implementation. Discussions repeatedly returned to the same essential questions: how to meet evolving regulatory expectations, how to design manufacturing that is robust and scalable, and how to ensure that patient needs remain at the centre of development. Alongside expert sessions, the event also created strong opportunities for networking and collaboration across the European ATMP community.
Across the programme, speakers highlighted the importance of aligning innovation with feasibility. Translational progress in ATMPs requires not only strong science, but also manufacturing strategies that can withstand operational realities, and regulatory approaches that support both safety and speed. The conference reflected an increasingly mature European perspective, one that is building the foundations for advanced therapies to become accessible and sustainable parts of healthcare.
This breakfast panel brought together speakers from Denmark, Sweden, and Norway to share how their countries balance collaboration and competition to build resilient national ATMP ecosystems. The discussion offered concrete examples of how coordination across institutions can accelerate development, strengthen capabilities, and reduce duplication, while still leaving space for healthy competition that drives excellence.
A key takeaway was that long term success depends on shared infrastructure, transparent partnerships, and a culture that supports joint problem solving across academia, hospitals, and industry.
From Lab to Clinic: Point of Care Anti CD19 CAR T Cell Therapy Induces Remission in Refractory Acquired Hemophilia A
An inspiring case study presented by Kalin Stoyanov from Medizinische Hochschule Hannover demonstrated the potential of point of care manufacturing in a clinical context. The session described how rapid, local production approaches can offer tangible benefits, especially for patients who have exhausted standard therapeutic options.
The presentation underscored the broader promise of point of care pathways: shortening time to treatment, improving responsiveness, and opening possibilities for settings where centralised manufacturing is not realistic.
Participation in PDA ATMP Conference 2025 reinforced the value of European knowledge exchange at a time when advanced therapies are entering a new phase of maturity. For CREATIC, these discussions support ongoing efforts to connect scientific development with regulatory readiness, manufacturing capability, and real patient impact.
